CRISPR Therapeutics AG buy skatcup
Start price
05.09.21
/
80%
€41.40
Target price
05.09.22
€200.00
Performance (%)
0.00%
End price
01.10.22
€41.40
Summary
This prediction ended on 01.10.22 with a price of €41.40. skatcup's BUY prediction for CRISPR Therapeutics AG closed unchanged from the start price. skatcup has 80% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| CRISPR Therapeutics AG | - | - | - |
| iShares Core DAX® | -2.926% | -4.228% | 9.878% |
| iShares Nasdaq 100 | 4.462% | 8.605% | 33.063% |
| iShares Nikkei 225® | 0.306% | 0.284% | 3.871% |
| iShares S&P 500 | 2.488% | 4.773% | 27.189% |
According to skatcup what are the pros and cons of CRISPR Therapeutics AG for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Good rating
High Investments for future growth
Capable Management
Good culture
Leading role in innovation
Strong uniques
Very differentiated customer and product portfolio
Growths much faster than the competition
Stable Large shareholder and/or long term investor
Market Leader or Top 3
Very small cyclical dependencies
Well known brand
Very Future proof/growth oriented business model
Cons
High valuation
Low dividend yield expected
Increased challenges to pay loans and raise capital
Higher risks for its business
Comments by skatcup for this prediction
In the thread CRISPR Therapeutics AG diskutieren
In the thread Trading CRISPR Therapeutics AG
Die von skatcup gewählte maximale Laufzeit wurde überschritten
Stopped prediction by skatcup for CRISPR Therapeutics AG
CRISPR Therapeutics AG
Start price
Target price
Perf. (%)
€41.40
25.02.20
25.02.20
€140.00
04.11.21
04.11.21
-
04.08.21
04.08.21
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
High valuation
Low dividend yield expected
